According to DelveInsight, the Hepatitis D treatment pipeline includes over six leading companies actively engaged in the development of more than six therapeutic candidates.
Hepatitis D Overview:
Hepatitis D, also known as delta hepatitis, is a liver infection caused by the hepatitis D virus (HDV) and occurs only in individuals already infected with the hepatitis B virus (HBV). Transmission happens through contact with infected blood or bodily fluids. The infection can be either acute and short-lived or develop into a chronic condition, often resulting in serious health issues, including permanent liver damage and potentially death. Individuals may contract hepatitis B and D at the same time (coinfection) or acquire hepatitis D after an existing hepatitis B infection (superinfection). Although there is no vaccine specifically for hepatitis D, vaccination against hepatitis B effectively prevents HDV infection as well.
Request for a detailed insights report on Hepatitis D pipeline insights
“Hepatitis D Pipeline Insight 2025” report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Hepatitis D Therapeutics Market.
Key Takeaways from the Hepatitis D Pipeline Report
DelveInsight’s Hepatitis D pipeline report depicts a robust space with 25+ active players working to develop 30+ pipeline therapies for Hepatitis D treatment.
In October 2025, Bluejay Therapeutics announces upcoming data presentations on Chronic Hepatitis D (CHD) and Chronic Hepatitis B (CHB) at the 2025 American Association for the Study of Liver Diseases (AASLD) The Liver Meeting®.
In September 2023, Eiger BioPharmaceuticals announced the discontinuation of its Phase III LIMT-2 study of peginterferon lambda in patients with chronic hepatitis D. This decision was made following a recommendation from the Data Safety Monitoring Board (DSMB) after their routine safety review.
Key Hepatitis D companies such as Eiger Biopharmaceuticals, Arrowhead Pharmaceuticals, Antios Therapeutics, PharmaEssentia, REPLICor, SomaGenics, Vir Biotechnology, VLP Biotech, and others are evaluating new drugs for Hepatitis D to improve the treatment landscape.
Promising Hepatitis D pipeline therapies in various stages of development include Lonafarnib, JNJ 73763989, and others.
Hepatitis D Pipeline Analysis
The report provides insights into:
The report provides detailed insights into the key companies that are developing therapies in the Hepatitis D Market.
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Hepatitis D treatment.
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Hepatitis D market.
Download our free sample page report on Hepatitis D pipeline insights
Hepatitis D Emerging Drugs
Lonafarnib: Eiger Biopharmaceuticals
JNJ 73763989: Arrowhead Pharmaceuticals
Hepatitis D Companies
Approximately six major companies are working on developing treatments for Hepatitis D. Among them, Eiger Biopharmaceuticals has the most advanced drug candidates, currently in Phase III of clinical development.
DelveInsight’s report covers around 22+ products under different phases of clinical development like
Late stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I) along with the details of
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Hepatitis D pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Intravenous
Subcutaneous
Oral
Intramuscular
Hepatitis D Products have been categorized under various Molecule types such as
Monoclonal antibody
Small molecule
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Hepatitis D Therapies and Key Companies: Hepatitis D Clinical Trials and advancements
Hepatitis D Pipeline Therapeutic Assessment
• Hepatitis D Assessment by Product Type
• Hepatitis D By Stage
• Hepatitis D Assessment by Route of Administration
• Hepatitis D Assessment by Molecule Type
Download Hepatitis D Sample report to know in detail about the Hepatitis D treatment market @ Hepatitis D Therapeutic Assessment
Table of Content
1. Report Introduction
2. Executive Summary
3. Hepatitis D Current Treatment Patterns
4. Hepatitis D – DelveInsight’s Analytical Perspective
5. Therapeutic Assessment
6. Hepatitis D Late-Stage Products (Phase-III)
7. Hepatitis D Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Hepatitis D Discontinued Products
13. Hepatitis D Product Profiles
14. Hepatitis D Key Companies
15. Hepatitis D Key Products
16. Dormant and Discontinued Products
17. Hepatitis D Unmet Needs
18. Hepatitis D Future Perspectives
19. Hepatitis D Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Hepatitis D Pipeline Reports Offerings
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/
